Wells Fargo Maintains Overweight on Tenet (THC) Feb 2026, PT $265

THC analyst rating: Wells Fargo maintained an Overweight rating on Tenet Healthcare Corporation (THC) and raised its price target to $265 on Feb 16, 2026. This action kept the firm’s positive stance while increasing modeled upside from $229. The move follows Tenet’s Q4 2025 results and 2026 adjusted EBITDA guidance. Meyka AI rates THC with a grade of A, reflecting S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. These notes are for information and not financial advice.

THC analyst rating: Wells Fargo action and price target details

Wells Fargo maintained Overweight on Feb 16, 2026 and raised the price target to $265 from $229. The research note highlighted stronger EBITDA trajectory and USPI outpatient momentum as justification. source

Price target change and investor implications

A higher price target increases implied upside and signals analyst confidence in cash flow and margin recovery. Investors should view the $265 target as a directional guide, not a guarantee.

THC analyst rating context tied to recent earnings and guidance

Tenet’s Q4 2025 results and 2026 adjusted EBITDA guidance led the update, linking operating performance to the analyst view. source

Analyst coverage history for Tenet Healthcare Corporation

Wells Fargo is the only firm in this update, but Tenet has seen sustained coverage from major brokers over multiple years. Historical coverage typically centered on USPI growth, hospital volumes, and margin stabilization.

Market cap, stock performance, and link to analyst moves

Tenet’s market cap is $20,310,223,500, and analyst notes like this can influence flows in the near term. Price reactions often follow guidance or target revisions, especially after earnings.

What the maintained Overweight means for investors

Maintaining Overweight signals confidence in relative outperformance versus peers and the market. For investors, it suggests holding or adding shares if the investor’s thesis relies on outpatient growth and EBITDA expansion.

Final Thoughts

Wells Fargo’s Feb 16, 2026 note kept an Overweight rating and raised the price target to $265, reflecting improved EBITDA outlook and USPI momentum. The single-firm update reinforces existing positive analyst sentiment but is not a market guarantee. Investors should balance the price target against valuation, execution risk, and Tenet’s guidance. Meyka AI rates THC with a grade of A; this grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Use the rating and target as part of a wider research process and consult your advisor before trading.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.